/주식/BEAT
BEAT

BEAT

USD

Heartbeam Inc. Common Stock

$1.810+0.030 (1.685%)

실시간 가격

Healthcare
Health Information Services
미국

가격 차트

Loading Chart...

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$1.780

고가

$1.830

저가

$1.740

거래량

0.00M

기업 기본 정보

시가총액

61.0M

산업

Health Information Services

국가

United States

거래 통계

평균 거래량

0.08M

거래소

NCM

통화

USD

52주 범위

저가 $1.45현재가 $1.810고가 $3.48

AI 분석 리포트

마지막 업데이트: 2025년 4월 29일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

BEAT (Heartbeam Inc. Common Stock): Analyzing Recent Moves & What Might Come Next

Stock Symbol: BEAT Generate Date: 2025-04-29 13:44:56

Alright, let's break down what's been happening with Heartbeam stock (BEAT) based on the latest info. We've got some fresh news, a look at the price chart over the last few months, and what an AI model is predicting short-term.

Recent News Buzz: What's the Vibe?

The news coming out recently sounds pretty good for Heartbeam.

Just today, we heard they hit key goals in a big study for their special 12-lead ECG tech. This is a big deal because these results are what they used when they sent their software application to the FDA back in January. Meeting clinical endpoints is a crucial step towards potential regulatory approval, which could open up market opportunities.

A few days earlier, on April 24th, they announced they're teaming up with another company called AccurKardia. Both companies work in the cardiac monitoring space, so this collaboration is about trying to push forward innovation in how heart activity is recorded and analyzed outside of a hospital. Partnerships like this can sometimes speed up development or expand reach.

So, the overall feeling from the news is definitely positive. They're hitting development milestones and making strategic moves.

Price Action: What's the Stock Been Doing?

Looking at the price history since late January, BEAT has had a bit of a rollercoaster ride, but the general trend until very recently was downwards. It started the period around the $2.15 to $2.40 mark, then slowly drifted lower through February and March, even dipping below $2.00.

Things got particularly rough in early April, with the price dropping sharply and hitting a low around $1.45.

Then came the news. Notice the jump on April 24th and 25th? The price shot up significantly, likely reacting to that collaboration announcement and perhaps anticipation of the clinical results news that followed. It went from around $1.62 to over $2.00 briefly.

Today, though, the price seems to be pulling back a bit from that recent spike. The last trade recorded is around $1.76.

The AI prediction for today is a slight drop (-1.28%), which fits with the current price being lower than yesterday's close. It then predicts small increases over the next couple of days (0.27% and 1.05%).

Putting It Together: Outlook & Strategy Ideas

Based on the positive news and the recent price reaction, followed by today's slight dip, here's one way to look at it:

The news provides a strong fundamental reason why someone might be interested in Heartbeam. The stock price clearly reacted positively to this news catalyst, showing investor excitement. However, it looks like that initial pop might be cooling off a little today, which the AI prediction also points to.

  • Apparent Near-Term Leaning: The situation seems to favor patience/monitoring right now, especially after the recent bounce and today's predicted dip. While the news is good, the price needs to show if it can hold onto these gains or find a new level of support after the initial reaction.
  • Potential Entry Consideration: If you're interested in BEAT because of the positive news, watching how the price behaves after this current dip could be key. A potential area to watch might be around the current price level ($1.70s) or slightly lower, if it stabilizes there and shows signs of bouncing back up. The recommendation data mentioned entry points around $1.87 and $1.92, which are above the current price, suggesting they might be waiting for the price to move back up towards those levels after this pullback.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always important. The recommendation data puts a potential stop-loss right at $1.76, which is the current price. This tells you that if the price falls below this level, it could signal that the recent bounce is failing. Setting a stop-loss just below recent support or that $1.76 level could be a way to limit potential losses if the stock continues to fall. For taking profits, the recommendation suggests $2.09, which is close to the recent high after the news – a reasonable target if the price recovers and moves higher.

Company Context

Remember, Heartbeam is a relatively small medical technology company focused on developing new ways to monitor heart health using advanced ECG tech. They have a small team (21 employees) and a modest market cap (around $59 million). This means the stock can be quite volatile, and news like hitting clinical endpoints or forming partnerships can have a much bigger impact than on a giant company. Their core business is directly tied to the kind of news we just saw, making these developments particularly relevant.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves significant risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

관련 뉴스

BusinessWire

HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern

더 보기
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time
BusinessWire

HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology

Milestone results formed the basis of HeartBeam's 12-lead ECG synthesis software application submitted to FDA in January 2025 HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming

더 보기
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology
BusinessWire

HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation

Collaboration brings together two leaders in ambulatory ECG recording and analysis HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized

더 보기
HeartBeam and AccurKardia Announce Strategic Collaboration to Advance Cardiac Monitoring Innovation

AI 예측Beta

AI 추천

약세

업데이트 시간: 2025년 5월 4일 오전 01:19

약세중립강세

57.6% 신뢰도

리스크 & 트레이딩

리스크 수준3/5
중위험
적합 대상
가치
트레이딩 가이드

진입점

$1.77

익절

$1.91

손절

$1.61

핵심 요소

PDI 33.0이(가) ADX 7.5과 함께 MDI 31.2 위에 있어 강세 추세를 시사합니다.
현재 가격이 지지선($1.79) 근처에 있어 잠재적인 매수 기회를 나타냅니다.
MACD 0.0048이(가) 신호선 0.0074 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기